OBJECTIVES: Hypoglycaemic episodes are a common side-effect of anti-diabetes therapy. The impact and associated costs of severe episodes (i.e. episodes that the patient is unable to treat themselves) has been extensively reported. There is less information about non-severe hypoglycaemic episodes (NSHE). The objective was to investigate the costs and resource use associated with NSHEs across a number of different countries in Europe. METHODS: The ‘Hypoglycaemia in Insulin Treated patients’ (HIT) study has recently been completed and reported for 11 countries across Europe, reporting data from 6,502 patients. Along with data on the frequency and impact of NSHE, the study also collected data on resource use associated with NSHEs.  Data from ten of the countries were utilized, along with published, country specific, cost data to calculate an average NSHE cost in each country. Resource use differed for different types of diabetes, costs for Type 1 diabetes (T1D), and Type 2 diabetes (T2D) are reported separately. RESULTS: NSHEs required additional blood glucose tests (3.3-8.2). The numbers differed depending on country, type of diabetes (T1D:3.3-7.7; T2D: 1.3-8.2) and whether the event was diurnal or nocturnal (min: 1.3-3.7; max: 6.2-8.2). Additionally a number (T1D: 0% - 16%; T2D: 3% - 23%), highest in Spain and Germany, of NSHEs resulted in contact with healthcare professionals. The average cost (per NSHE) to the healthcare system was €4.34 (T1D - range €2.10 – €6.80) ; and €6.20 (T2D - range €2.10 – €11.20). CONCLUSIONS: NSHEs pose a substantial burden to healthcare systems, and society. While individual episodes incur only a small cost, episodes are common, and the frequency of NSHEs means that costs for a country can be considerable. In addition to this – the patients will often also bear the cost of rescue treatments such as a snack or glucose tablets.